Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naïve myelofibrosis.

View Full Paper
Ask AI
Bookmark
Share

Authors

JMJohn MascarenhasKMKeri MaherRRRaajit K. Rampal

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mascarenhas et al. (2024) studied this question.

synapsesocial.com/papers/68e66c53b6db6435875f720dhttps://doi.org/10.1200/jco.2024.42.16_suppl.tps6594
View Full Paper
Ask AI
Bookmark
Share